6h-05 (tfa)

Jagged-1 (188-204) TFA(219127-21-6 free base) is a fragment of the JAG-1 protein. JAG-1 is Notch ligand, a peptide that is the most conspicuously expressed ligand in skin. JAG-1 induces epidermal maturation. Exposing submerged keratinocytes monolayers to JAG-1 with elevated calcium concentration produces stratification with loricrin expression and NF-alphaB activation.

Crosstide is a peptide analog of glycogen synthase kinase α/β fusion protein sequence which is a substrate for Akt.

H-Ala-Ala-Tyr-OH acetate can be synthesized mutant peptides.

2-Furoyl-LIGRLO-amide TFA(729589-58-6 free base) is a potent and selective protease-activated receptor 2 (PAR2) agonist.

β-amyloid 1-11 acetate is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.

FSLLRY-NH2 TFA is a is a protease-activated receptor 2 (PAR2) inhibitor. Reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice. Blocks ERK activation and collagen production in isolated cardiac fibroblasts. Also reduces symptoms in a mouse model of dermatophyte-associated itch.

Allatostatin IV TFA, an octapeptide amine, is a member of the allatoregulatory peptide family found in insects which either inhibit (allatostatins) or stimulate (allatotropins) juvenile hormone (JH) synthesis.

Boc-Gly-Gly-Phe-Gly-OH TFA is a self-assembly of N-protected and C-protected tetrapeptides and is a protease cleaved connector for antibody-drug binding (ADC).

Phytochelatin 6 TFA, a metal-binding compound synthesized by plants, can potentially decrease the bioavailability of dietary toxic metals like cadmium [1].

Arg-gly-glu -Ser(TFA) is a RGD related polypeptide that controls the inhibition of fibrinogen binding to activated platelets by RGDS.

PACAP (6-38), human, ovine, rat TFA is a potent PACAP receptor antagonist with IC50s of 30, 600, and 40 nM for PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.

H-Lys(Tfa)-OH is an inhibitor of L-lysine cyclodeaminase.

Mad1 (6-21) TFA, a fragment encompassing amino acids 6 to 21 of the Mad1 protein, exhibits a strong affinity for the PAH2 domain of mammalian Sin3A with a dissociation constant (Kd) of approximately 29 nM [1].

FibrinopeptideB,human is a 14-amino acid polypeptide released from the amino terminus of the fibrinogen segment.

Cardiotoxin Analog IV (6-12) TFA, a partial peptide of Cardiotoxin Analog IV, is derived from the venom of the Taiwan Cobra, showcasing the unique properties of snake venom cardiotoxin[1].

PAR 4 (1-6) TFA (GYPGQV TFA), a hexapeptide derived from protease-activated receptor 4 (PAR 4), serves as a specific agonist for PAR 4. This fragment of PAR 4 [1] exhibits targeted activation properties.

TRAP-6 amide TFA is a PAR-1 thrombin receptor agonist peptide.

H-Val-Pro-Pro-OH(TFA), a proline peptide derivative from milk, is an ACE inhibitor with IC50 of 9 M.

H-Ala-Ala-Tyr-OH TFA can be synthesized mutant peptides.

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a peptide that acts as an agonist for the proteinase-activated receptor (PAR-3)[1].

CGGRGD TFA is synthesized via solid-phase peptide synthesis technique and the surface of PCL fibers is aminolysised by amino 2-cyanobenzothiazole followed by the addition of 2-cyanobenzothiazole (CBT)[1].

Angiogenin (108-122) TFA is an angiogenin peptide.Angiogenin (108-122) acts as a therapeutic agent for the prophylaxis and/or treatment of cancer, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an autoimmu

PKA Inhibitor Fragment (6-22) amide TFA (PKA Inhibitor Fragment (6-22) amide TFA) is an inhibitor of the highly potent cAMP-dependent protein kinase A (PKA) inhibitor (Ki: 2.8 nM).PKA Inhibitor Fragment (6-22) amide TFA reverses the pain-relieving effects of low levels of morphine in mice.

Melanin Concentrating Hormone (MCH), a 19 amino acid cyclic peptide, is largely expressed in the hypothalamus. Melanin Concentrating Hormone is implicated in the control of general arousal and goal-orientated behaviours in mammals, and appears to be a key

CALP3 TFA is a potent Ca2+ channel blocker that activates EF-hand motifs of Ca2+-binding proteins. It can functionally mimic increased [Ca2+]i by modulating the activity of Calmodulin, Ca2+ channels, and pumps.

Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.

NLS-StAx-h TFA is a selective and cell-permeable stapled peptide that inhibits Wnt signaling, demonstrating an IC50 value of 1.4 μM and effectively suppressing β-catenin-transcription factor interactions. This compound exhibits anti-proliferative effects on cancer cells [1] [2].

H-Val-Pro-Pro-OH (TFA) is an inhibitor of angiotensin I converting enzyme (ACE) (IC50: 9 μM).H-Val-Pro-Pro-OH (TFA) is a milk-derived proline peptide derivative.

Pap12-6, an antibacterial peptide originating from the first twelve N-terminal amino acids of papiliocin found in P. xuthus larvae, exhibits activity against a range of eight Gram-negative bacteria (e.g., E. coli, P. aeruginosa, S. syphimurium with MIC50s=4-8 µM) and Gram-positive bacteria (e.g., S. aureus, methicillin-resistant S. aureus 3126, B. subtilis, and S. epidermidis with MIC50s=4-8 µM), without compromising the viability of human erythrocytes, mouse RAW 264.7 macrophages, human HaCaT keratinocytes, or human HEK293 kidney cells at 25 µM. It causes membrane depolarization in E. coli at 4 and 8 µM and, upon preincubation at 10 µM, decreases nitrite (NO2-), Tnf-α, and Il-6 secretion in LPS-stimulated RAW 264.7 macrophages. In a murine model, Pap12-6 enhances survival rates and diminishes colony forming units (CFUs) in several organs upon E. coli infection at 10 mg/kg and 1 mg/kg doses, respectively. Additionally, at a 1 mg/kg dose, it lowers serum aspartate aminotransferase (AST) and alanine transaminase (ALT) levels, as well as blood urea nitrogen levels in E. coli-induced sepsis, indicating its therapeutic potential for bacterial infections without affecting host cell viability.

H-β-Ala-AMC TFA is a substrate for aminopeptidase. Building block for synthesizing the fluorogenic vanin I substrate pantothenate-AMC.

CRF(6-33)(human) TFA acts as a competitive inhibitor of the Corticotropin-Releasing Factor Binding Protein (CRF-BP), selectively interacting with CRF-BP without affecting post-synaptic Corticotropin-Releasing Factor receptors. This compound demonstrates an anti-obesity effect, as evidenced by studies [1] [2].

Gp100 (25-33), human TFA is a 25-33 amino acid fragment of human melanoma antigen.Gp100 (25-33), human TFA is a 9-amino acid (AA) epitopes restricted by h-2db and recognized by T cells.

Angiotensin I/II (1-6) TFA is a chemical compound comprising amino acids 1-6. It is derived from the Angiotensin I/II peptide, which is formed by the cleavage of the precursor angiotensinogen by renin. The resulting Angiotensin I is then hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

Caerulein, desulfated TFA is Caerulein after desulfurization.Caerulein is a deceptide with the same five carboxy-terminating amino acids as gastrin and cholecystatin (CCK)..

Urotensin II, mouse TFA is an endogenous ligand for the orphan GPR14 or SENR. It is a potent vasoconstrictor.

Cardiotoxin Analog (CTX) IV (6-12) is a part peptide of Cardiotoxin Analog (CTX) IV. Cardiotoxin analogues IV isolated from the venom of Taiwan Cobra.